Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis

By Iwamoto Jun   Takeda Tsuyoshi   Sato Yoshihiro  

Current Medical Research and Opinion, Vol. 22, Iss. 5, 2006-05 ,pp. : 919-928

Informa Healthcare

Access to resources Recommend Favorite

Cost-effectiveness of risedronate for the treatment of osteoporosis and prevention of fractures in postmenopausal women

By Kanis J.   Borgstrom F.   Johnell O.   Jonsson B.  

Osteoporosis International, Vol. 15, Iss. 11, 2004-11 ,pp. : 862-871

Springer Publishing Company

Access to resources Recommend Favorite

Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis

By Sebba Anthony I.   Bonnick Sydney Lou   Kagan Risa   Thompson Desmond E.   Skalky Carol S.   Chen Erluo   de Papp Anne E.    

Current Medical Research and Opinion, Vol. 20, Iss. 12, 2004-12 ,pp. : 2031-2041

Informa Healthcare

Access to resources Recommend Favorite

Skeletal pain in postmenopausal women with osteoporosis: prevalence and course during raloxifene treatment in a prospective observational study of 6 months duration

By Scharla S.   Oertel H.   Helsberg K.   Kessler F.   Langer F.   Nickelsen T.  

Current Medical Research and Opinion, Vol. 22, Iss. 12, 2006-12 ,pp. : 2393-2402

Informa Healthcare

Access to resources Recommend Favorite

Determinants of non-compliance with bisphosphonates in women with postmenopausal osteoporosis

By Penning-van Beest Fernie J. A.   Erkens Joëlle A.   Olson M.   Herings Ron M. C.  

Current Medical Research and Opinion, Vol. 24, Iss. 5, 2008-05 ,pp. : 1337-1344

Informa Healthcare

Access to resources Recommend Favorite